Considerations for affinity capture in an AAV platform downstream process

In the rapidly evolving field of gene therapy, AAV vectors have shown increasing therapeutic promise. In recent years, a variety of different therapies using various AAV serotypes have received regulatory approval, and hundreds more are in clinical trials. From discovery to the clinic, as the quest to produce new, high-quality AAV molecules intensifies, an efficient and scalable platform purification process for multiple AAV serotypes is advantageous for both drug developers and CDMOs. This article explores the considerations when evaluating a platform affinity capture step for the purification of AAV vectors. Specificity, binding capacity, purity, yield, scalability, and reusability parameters will be addressed.

Please enter your email to access content Read now